Eyewire News

Featured Story

Duravyu Misses Primary Endpoint in Phase 3 LUGANO Trial but Reduces Treatment Burden in Wet AMD image

08.17.2026

Duravyu Misses Primary Endpoint in Phase 3 LUGANO Trial but Reduces Treatment Burden in Wet AMD

Key Takeaways Duravyu 2.7 mg missed the primary noninferiority endpoint versus on-label aflibercept 2 mg in the full LUGANO dataset, but an ad hoc analysis excluding 9 of 211 patients (4%) showed noninferiority (nominal P = .0096). Duravyu 2.7 mg reduced treatment burden by 42% versus aflibercept 2 mg (nominal P < .0001); 76% of patients were supplement-free through week 32 and 54% remained supplement-free through week 56.

Read Story

Latest News Stories

08.17.2026

CMS Strengthens Prior Authorization Transparency Requirements

08.17.2026

CORE Publishes Contact Lens Update Issue Focused on Presbyopia Communication

08.17.2026

WCO, Alcon, and IACLE Expand Access to Dry Eye Education Tools

08.14.2026

European Consortium Launches Human Trials of Gene-Silencing Eye Drops for Rare Corneal Diseases

08.14.2026

Large UK Study Examines Impact of Anti-VEGF Treatment for DME on Progression to Proliferative Diabetic Retinopathy

08.13.2026

First Patient Receives Investigational Regenerative Cell Therapy for Non-Syndromic Retinitis Pigmentosa

08.13.2026

Prevent Blindness Raises Concerns Over Proposed Head Start Vision Screening Changes

08.13.2026

Annexon Adds Month 24 Primary Endpoint to Phase 3 ARCHER II Trial of Vonaprument for GA

Alfasigma Expands Presence in Europe with Acquisition of Nordic Pharma, Maker of Lacrifill Canalicular Gel image

08.12.2026

Alfasigma Expands Presence in Europe with Acquisition of Nordic Pharma and the Lacrifill Canalicular Gel

08.12.2026

NovelMed Advances NM5072 for GA, Complement-Associated Retinal Diseases

08.11.2026

First Patient Dosed in Artelo Biosciences' Phase 2 Study of Synthetic Cannabinoid for Glaucoma

08.11.2026

FDA Accepts Belite Bio’s NDA for Tinlarebant in Stargardt Disease

$Omega Ophthalmics Closes $7 Million Financing, Schedules FDA Meeting for Gemini Refractive Capsule image$

08.11.2026

Omega Ophthalmics Closes $7 Million Financing, Schedules FDA Meeting for Gemini Refractive Capsule

BostonSight Initiates Trial Examining Mental Health Outcomes with PROSE Treatment and Scleral Lenses image

08.11.2026

BostonSight Initiates Trial Examining Mental Health Outcomes with PROSE Treatment and Scleral Lenses

08.10.2026

PracticeAmerica Launches Physician-to-Physician Marketplace for Independent Practice Transitions

08.10.2026

Oculis to Acquire Global Rights to Privosegtor from Accure Therapeutics

08.10.2026

Nicox Licensee Submits Application for Glaucoma Candidate NCX 470 in China

Contact Lens Institute Taps Olympic Medalist Nancy Kerrigan for Contact Lens Care Campaign image

08.10.2026

Contact Lens Institute Taps Olympic Medalist Nancy Kerrigan for Contact Lens Care Campaign

WaveFront Dynamics Expands Scleral Lens Options Through Bausch + Lomb, WAVE Eye Care Integrations image

08.10.2026

WaveFront Dynamics Expands Scleral Lens Options Through Bausch + Lomb, WAVE Eye Care Integrations

View More